Savient Sues More Generic Cos. Over Weight-Gain Drug

Law360, New York (December 4, 2006, 12:00 AM EST) -- Drug manufacturer Savient Pharmaceuticals Inc. has launched a patent infringement suit against Novartis AG unit Sandoz Pharmaceuticals and Upsher-Smith Laboratories Inc. over their generic version of Savient’s lucrative weight-gain drug, Oxandrin.

Savient’s suit, filed Monday in the U.S. District Court for the District of New Jersey, was prompted by the FDA’s denial Friday of two of its citizens’ petitions filed in February 2004 and September 2005, and after Savient secured “reliable information” that the FDA had approved Sandoz’ and Upsher-Smith’s abbreviated new drug applications (ANDAs) for...
To view the full article, register now.